Trends in Cancer
@trendscancer
Followers
5K
Following
2K
Media
650
Statuses
5K
Trends in Cancer is a leading reviews journal covering advances in cancer research and oncology published by Cell Press. Tweets by Editor Danielle Loughlin.
Cambridge, MA
Joined September 2015
A perfect holiday-season read with hot chocolate & cookies ☕️🍪❄️ @trendscancer “Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics” Led by our rising star physician-scientist @BetulGokYavuz1 ✨ Free link:
0
5
19
📢 How does #epigenetics fuel #chromosome #instability in #cancer? Together with @IlioVitale and @deadoc80, we highlighted two exciting recent papers from @NatureGenet and @CD_AACR in our newly published @trendscancer Spotlight! Check it out here 👉 https://t.co/Aqhmfvow4Q
2
4
8
Great Spotlight in @trendscancer by @psychonaut together with @IlioVitale and @deadoc80, discussing the role of epigenetics as a driver of #chromosome #instability in #cancer 🔥
📢 How does #epigenetics fuel #chromosome #instability in #cancer? Together with @IlioVitale and @deadoc80, we highlighted two exciting recent papers from @NatureGenet and @CD_AACR in our newly published @trendscancer Spotlight! Check it out here 👉 https://t.co/Aqhmfvow4Q
0
2
3
We're excited to host a distinguished lineup of speakers at @CellSymposia #CSHallmarks2026, including keynotes Johanna Joyce @Joycelab & Faisal Mahmood @AI4Pathology View the full speaker lineup: https://t.co/U0IyTmpVf4
0
1
1
What’s true in #PancreaticCancer precursor lesions is also true in #ColorectalCancer precursor lesions. @cncurtis @SnyderShot @StanfordMed demonstrate polyclonal origin of adenomas in patients with FAP. Cancer as a manifestation of convergent evolution! https://t.co/Bnqko2Z2Y8
2
60
205
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer https://t.co/6N1W6vEJdm
1
12
21
Adding to this week reading list; this direction seems like a major unresolved puzzle.
Two fantastic stories published ~a year apart with striking confluence in findings - while age is the single most important risk factor for cancer, aging can also limit the ability of cells to undergo neoplastic transformation. https://t.co/k3A4nvttVn
https://t.co/fNiXBr14tp
0
3
15
Companion paper in @NatureCancer from @StraussmanR @WeizmannScience with comparable findings: Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures https://t.co/9BZf7K6Y9g
Provocative new data in @NatureMedicine from @JenWargoMD @nadim_ajami & colleagues @MDAndersonNews Microbial signals in primary and metastatic brain tumors https://t.co/6htdGy7vPt Orthogonal validation using multiple platforms provides support for this observation
2
17
54
Save the date for Cell Symposia: Hallmarks of cancer 2026! 📆November 1–3, 2026 📍Sitges, Spain 🔗 https://t.co/g8DzNdVy62
@CellSymposia #CSHallmarks2026 #TumorImmunology #CancerNeuroscience #ImmunoOncology #PrecisionOncology #CancerMicrobiome #ClinicalOncology
0
0
1
Thrilled to share our open-access review on @trendscancer! We explore HLA allotype-driven cancer immunity, discuss current issues, and propose innovative, broad-spectrum solutions. Read here: https://t.co/tRqVfyujGL
#CancerResearch #HLA #Immunotherapy @PatrickHwuMD @MoffittNews
#ScienceSaturday ❓ Why do some cancer patients miss out on promising immunotherapy treatments? ➡ Our new article in Trends in Cancer explores how many advanced cancer therapies, such as T cell-based treatments, are designed for people with a specific tissue type called
0
2
4
A topic we don’t think about enough in the clinic (largely logistical) but which keeps showing up - time of day & impact of immunotherapy. Commentary in @trendscancer: Time-of-day dependency of adoptive cell therapies https://t.co/BMoqu1WfnB Circadian rhythms matter!
5
31
161
Is gamma-delta CAR T the next wave? Congrats Fraietta Lab and @JoeFraietta!
Happy to announce publication of our new paper: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy | Nature Biomedical Engineering Congratulations, Angel and Team!!!
1
8
44
Cancer stem cells (CSC) are elusive and one of the reasons for resistance to treatment. Machine learning led to discovery of a way to promote their self-destruction (apoptosis) https://t.co/LzMIvibtSJ
3
51
173
Tumor-on-chip models of CAR-T cell therapy @NatureBiotech
https://t.co/J6sc9yobAp
https://t.co/f33yyAxSEh
https://t.co/cNC60NnTBD
@CellStemCell
0
35
132
Congrats to my postdoc, Aya Ludin Tal, on her Cell paper. Her work using live imaging in zebrafish identifies CRATERS on the surface of melanoma - immune hubs for T cells. CRATERS in human melanoma are the best predictors of immunotherapy success. https://t.co/TWaWJUZdTp
5
23
121
A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors https://t.co/4EjvE8JRAE
3
98
394
Our new, comprehensive review on CAR T cell persistence is officially published in @CellCellPress @trendscancer. Fantastic work from lead authors @kpmueller1 @JGrenierMDPhD. Link to the full article: https://t.co/4a0lsoqHtm
2
34
127
New in @Cancer_Cell from @MDAndersonNews colleagues @BullmanLab @CJohnstonLab1 on effects of tumor #microbiome on cancer cell cycle & chemoresistance Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest https://t.co/5ec0sGEh8s
1
17
75
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer https://t.co/BXqMfuxxjM
2
33
121